CHAPEL HILL, N.C., July 6, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the Global Technology Community 9th Anti-Infectives Partnering and Deal-Making Conference on July 9 to 10 at the San Francisco Airport Marriott Waterfront Hotel in San Francisco. Dr. Fernandes will participate in a panel discussion entitled Current Trends and Future Anti-Infectives Development to be held at 10:30 a.m. PDT on July 9. She will also give a presentation at noon PDT on July 10 that will provide an overview of solithromycin, Cempra's fluoroketolide in clinical development for the treatment of community-acquired bacterial pneumonia.
About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.
Investor Contacts: Robert E. Flamm, Ph.D.Russo Partners, LLC(212) 845-4226 Robert.email@example.comAndreas MarathovouniotisRusso Partners, LLC(212) 845-4235 Andreas.firstname.lastname@example.org Media Contact:Elliot Fox Russo Partners, LLC (212) 845-4253 Elliot.email@example.com SOURCE Cempra, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV